

Colombia

Prostate Cancer Factsheet: Insights & Key Developments

Key Insights on Prostate Cancer
Care and Infrastructure

Core Pillars:

1. Infrastructure
2. Treatment Access, Research Funding and Awareness Campaigns
3. Survival Rates, Early Detection and Palliative Care
4. Utilization of Biomarkers
5. Clinical Guidelines
6. Reimbursement
7. Prostate Cancer Screening

Prostate cancer remains one of the most prevalent cancers worldwide, affecting millions of individuals each year. Despite advancements in diagnostics, treatment, and awareness, disparities in access to care, molecular testing, and specialized centers persist.


This factsheet provides a comprehensive overview of key pillars shaping Prostate cancer care, including specialized infrastructure, treatment accessibility, research funding, early detection, and palliative care.

- **Incidence share:** Among the top 5 most common cancers in Colombian men.
- **Incidence rate:** Approximately 25–30 per 100,000 men per year, in line with Latin American averages.
- **Total new cases (2022):** Estimated around 12,000–15,000 men.
- **Daily diagnoses (2022):** Around 35–40 men per day.
- **Deaths (2022):** Likely 3,000–4,000 men annually.
- **5-year survival rate:** Estimated in the 70–80% range.
- **Most affected age group:** Primarily men aged 65–75 and above.
- **Screening participation:** Opportunistic PSA testing; no national organized screening.

Colombia



Infrastructure



Strengths

- Health coverage reaches over 90% of the population, linking clinics in smaller towns to urban cancer centres for diagnostics and treatment.
- Bogotá, Medellín, and Cali host modern tertiary hospitals with MRI, linear accelerators, biopsy services, and robotic surgery equipment.

Weakness


- Rural and remote regions suffer from a severe shortage of oncology services; many municipalities lack hospital-based cancer care.
- Diagnostic delays of **several weeks to months** are common outside urban centers due to limited imaging and biopsy capacity.

Opportunity

- Establishing regional oncology hubs in underserved departments would bring diagnostics closer to rural populations.
- Investment in mobile MRI and biopsy units could significantly reduce delay and increase timely detection in remote regions.

Threats


- Continued under-funding of infrastructure could prevent expansion to high-need areas as prostate cancer incidence grows.
- Geographic barriers and poor transport infrastructure could undermine patient access and follow-up compliance



Country	Specialized Centers	Genetic & Molecular Testing Infrastructure
South Africa		
Kenya		
Nigeria		
Egypt		
Morocco		
Algeria		
Ethiopia		
India		
Japan		
South Korea		
China		
Thailand		
Singapore		
United Kingdom		
Germany		
France		
Netherlands		
Sweden		
Italy		
Spain		
Poland		
Mexico		
Brazil		
Argentina		
Chile		
Colombia		
United States		
Canada		
Australia		
New Zealand		
Greece		
Rwanda		
Uganda		
Serbia		
Saudi Arabia		
UAE		
Syria		
Indonesia		
Vietnam		
Philippines		
Russia		
Malaysia		

Colombia

Treatment Access, Research Funding and Awareness Campaigns



Strengths

- Public insurance plans (contributory and subsidized) cover surgery, hormonal therapy, and radiotherapy for prostate cancer across socio-economic groups.
- National initiatives and NGOs have implemented men's health events and prostate awareness programs in cities and some rural zones.

Weakness

- Prostate cancer research funding remains heavily concentrated in Bogotá and Medellín, limiting insight into regional and Afro-Colombian risk patterns.
- Awareness campaigns have had limited rural penetration; stigma and misconceptions persist, particularly in poorer communities.

Opportunity

- Expanding mobile screening and educational campaigns into high-risk Afro-Colombian and indigenous communities could boost early detection.
- Public-private partnerships can promote population-based research funding to support nationwide epidemiology and clinical trials.

Threats

- If funding remains centralized, regional disparities in data and patient outcomes will persist and widen.
- Cultural barriers around masculinity and stigma may continue to deter men from seeking screening or treatment.



5. Strong healthcare infrastructure with comprehensive treatment access, high research funding, and nationwide awareness campaigns. Patients have access to advanced therapies, clinical trials, and widespread early detection programs.




4. Well-developed system with good treatment availability, strong research funding, and effective but regionally focused awareness campaigns. Some disparities may exist in rural areas or between public and private sectors.






























































































































3. Moderate development, with specialized treatments available in major hospitals, research funding concentrated on specific cancers, and occasional but limited awareness efforts. Healthcare access may be restricted by cost or geography.



2. Limited system where cancer treatment is available only in select urban centers, research funding is minimal or sporadic, and awareness campaigns are rare or underfunded. Patients often face long wait times or financial barriers.




1. Poor infrastructure with severe barriers to treatment, little to no research funding, and lack of structured awareness campaigns. Cancer care is largely inaccessible, with many patients relying on out-of-pocket expenses or external aid.

Country	Treatment Access	Research Funding	Awareness Campaigns
South Africa			
Kenya			
Nigeria			
Egypt			
Morocco			
Algeria			
Ethiopia			
India			
Japan			
South Korea			
China			
Thailand			
Singapore			
United Kingdom			
Germany			
France			
Netherlands			
Sweden			
Italy			
Spain			
Poland			
Mexico			
Brazil			
Argentina			
Chile			
Colombia			
United States			
Canada			
Australia			
New Zealand			
Greece			
Rwanda			
Uganda			
Serbia			
Saudi Arabia			
UAE			
Syria			
Indonesia			
Vietnam			
Philippines			
Russia			
Malaysia			

Colombia

Survival Rates, Early Detection and Palliative Care



Strengths

- Urban tertiary hospitals can achieve **90%+ five-year survival** for localized prostate cancer treated early.
- Palliative care services are increasingly integrated into cancer centres in major cities, offering comprehensive symptom management.

Weakness

- National five-year survival hovers closer to 70–75%, trailing many higher-income countries.
- Men in subsidized insurance plans or rural areas often present with late-stage disease and lower survival outcomes.

Opportunity

- Implementing risk-based screening programs can shift detection to earlier stages, improving survival across all regions.
- Scaling up district-level palliative care teams would support a larger portion of men with advanced or metastatic disease.

Threats

- Persistent late-stage presentation in underserved areas could suppress national survival improvements.
- Growing case numbers without expanded care continuity may overwhelm palliative services.


5. High survival rates, strong early detection programs, and well-established palliative care services. Patients have access to timely diagnosis, advanced treatments, and comprehensive end-of-life care.
4. Good survival rates, effective early detection efforts, and accessible but regionally limited palliative care. Some disparities may exist in rural areas or for specific cancer types.
3. Moderate survival rates, early detection available but not widespread, and palliative care services mainly in urban centers. Some patients experience delays in diagnosis or limited end-of-life care.
2. Low survival rates, early detection efforts are inconsistent or underfunded, and palliative care is minimal or only available in select hospitals. Cancer patients face significant access barriers.
1. Very low survival rates, poor early detection infrastructure, and almost no palliative care services. Many patients are diagnosed late and lack proper support for pain management and end-of-life care.

Country	Survival Rates	Early Detection	Palliative Care
South Africa			
Kenya			
Nigeria			
Egypt			
Morocco			
Algeria			
Ethiopia			
India			
Japan			
South Korea			
China			
Thailand			
Singapore			
United Kingdom			
Germany			
France			
Netherlands			
Sweden			
Italy			
Spain			
Poland			
Mexico			
Brazil			
Argentina			
Chile			
Colombia			
United States			
Canada			
Australia			
New Zealand			
Greece			
Rwanda			
Uganda			
Serbia			
Saudi Arabia			
UAE			
Syria			
Indonesia			
Vietnam			
Philippines			
Russia			
Malaysia			

Colombia



Utilization of Biomarkers



Strengths

- PSA testing is reliably available in both public and private primary care and oncology settings across the country.
- Leading research sites are piloting genomic profiling initiatives to identify biomarkers relevant to Colombian patients.

Weakness


- Access to advanced diagnostics like genomic testing, liquid biopsy, or multi-marker panels is confined to a handful of urban academic centres.
- Similarly, clinician familiarity with interpreting biomarker results is uneven, particularly outside specialized settings.

Opportunity


- Integrating low-cost biomarker triage tools (e.g. risk calculators, free PSA) into primary care could increase detection accuracy.
- Partnering with biotech companies to subsidize broader genomic testing could democratize access and fuel personalized treatment.

Threats

- Overreliance on PSA alone risks overtreatment of indolent cancers or missed aggressive disease without robust follow-up.
- Without reimbursement reform, advanced biomarker testing may remain unavailable to low-income and rural patients.



Moderate utilization, often restricted to major hospitals or private healthcare settings. Some patients may not receive biomarker testing due to cost or limited availability in public healthcare systems.




Biomarker testing is available but underutilized, with significant barriers such as high costs, lack of awareness, or limited infrastructure. Many patients may not receive recommended biomarker assessments.





Biomarker testing is rarely performed, often due to lack of infrastructure, awareness, or financial barriers. Patients typically do not receive targeted therapies based on biomarker status.

Colombia



Colombia

Clinical Guidelines



	Very High	High	Medium	Low	Very Low
Clinical Guideline Implementation	✗	✗	○	✗	✗
Feasibility of Integration	✗	✗	○	✗	✗
Adoption of International Guidelines	✗	✗	○	✗	✗
Engagement with Updates	✗	✗	○	✗	✗
ESMO Guidelines Implementation	✗	✗	○	✗	✗

Colombia



Reimbursement



Strengths

- Both main insurance regimes offer universal coverage of essential diagnostics and treatments—ensuring financial access for most men.
- Centralized procurement by national agencies helps contain costs of standard surgical, radiation, and hormonal therapies.

Weakness

- Reimbursement for novel diagnostics or advanced therapies is inconsistent, especially under the subsidized plan.
- Patients frequently bear out-of-pocket costs for molecular testing or newer agents, creating access inequity between regimes.

Opportunity

- Policy expansion to include reimbursement for genomic biomarker tests or targeted drugs could promote precision oncology.
- Bundled care pathways—covering screening to follow-up—might reduce interval delays and improve care coordination.


Threats

- Without extending coverage to advanced care, low-income patients may suffer poorer outcomes despite basic access.
- Escalating drug costs may pressure insurers and limit future reimbursement of novel therapies.


- A structured reimbursement system exists, ensuring biomarker testing is covered through national healthcare systems, insurance, or public-private partnerships. Patients face no direct financial burden.
- A reimbursement framework is in place, but patients may still have out-of-pocket expenses such as co-pays, limited coverage, or financial caps on testing.
- No formal reimbursement system exists, meaning patients must fully cover the cost of biomarker testing out-of-pocket.

Country	Reimbursement Framework	No-cost Access
United States	●	●
United Kingdom	●	●
Canada	●	●
Australia	●	●
Germany	●	●
France	●	●
Netherlands	●	●
Sweden	●	●
Italy	●	●
Spain	●	●
Poland	●	●
Japan	●	●
South Korea	●	●
China	●	●
India	●	●
Singapore	●	●
Thailand	●	●
South Africa	●	●
Kenya	●	●
Nigeria	●	●
Egypt	●	●
Morocco	●	●
Algeria	●	●
Ethiopia	●	●
Mexico	●	●
Brazil	●	●
Argentina	●	●
Chile	●	●
Colombia	●	●
New Zealand	●	●
Greece	●	●
Rwanda	●	●
Uganda	●	●
Serbia	●	●
Saudi Arabia	●	●
UAE	●	●
Syria	●	●
Indonesia	●	●
Vietnam	●	●
Philippines	●	●
Russia	●	●
Malaysia	●	●

Colombia



Prostate Cancer Screening



Country	Prostate Cancer Screening
United States	Annual LDCT (50–80 years, high-risk smokers)
United Kingdom	LDCT for high-risk individuals (55–74 years)
Canada	LDCT for high-risk individuals (55–74 years)
Australia	No national program, high-risk groups advised LDCT
Germany	No national program, under evaluation
France	No national LDCT screening
Netherlands	Participating in European screening studies
Sweden	No national LDCT screening
Italy	Regional pilot LDCT screening
Spain	No national LDCT program
Poland	No national program
Japan	No national LDCT program
South Korea	LDCT for high-risk individuals (50–74 years)
China	No national LDCT program
India	No national LDCT program
Singapore	No national LDCT program
Saudi Arabia	No national LDCT program; some hospital-based opportunistic screening
UAE	No national LDCT program; early-stage pilot studies ongoing in select hospitals
Syria	No national LDCT program; screening not prioritized due to conflict
Malaysia	No program; high-risk CT pilots

Country	Prostate Cancer Screening
Thailand	No national LDCT program
South Africa	No national LDCT program
Kenya	No national LDCT program
Nigeria	No national LDCT program
Egypt	No national LDCT program
Morocco	No national LDCT program
Algeria	No national LDCT program
Ethiopia	No national LDCT program
Mexico	No national LDCT program
Brazil	No national LDCT program
Argentina	No national LDCT program
Chile	No national LDCT program
Colombia	No national LDCT program
New Zealand	No national LDCT program
Greece	No national LDCT program
Rwanda	No national LDCT program
Uganda	No national LDCT program
Serbia	No national LDCT program
Indonesia	No national LDCT program; opportunistic screening in private sector
Vietnam	No national LDCT program; early pilot screening studies in Hanoi and Ho Chi Minh
Philippines	No national LDCT program; feasibility and awareness programs under discussion
Russia	No formal national LDCT program; regional pilot screening programs in large cities